Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Sezary Syndrome: early-phase trial registry
6 of 14 indexed Sezary Syndrome trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 6 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Sezary Syndrome: 14 US clinical trials tracked, 6 recruiting.
Sezary Syndrome is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 2 of these trials.
Enrollment posture brief
Registry condition sezary-syndrome
OPEN 6 | RECR 43% | LATE 1 | EARLY 9 | RANK #1230 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (AML) (43% recruiting · 7 trials)
Sezary Syndrome lists 6 open slots (43% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Sezary Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Sezary Syndrome is recruiting below its size-band peers.
6 of 14 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Sezary Syndrome trials is spread across many organizations.
City of Hope Medical Center accounts for 2 of 14 trials (14.3%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Sezary Syndrome trials plan to enrol fewer than 100 people.
Median target enrolment is 34 among the 14 trials that report a genuine target (sentinel values excluded). 11 of those (78.6%) plan for fewer than 100 participants.
-
Sezary Syndrome research is mostly interventional.
10 interventional and 4 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Tissue Repository: CTCL Collection Protocol
Columbia University
NCT02840747
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
University of Pittsburgh
NCT00177268
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Memorial Sloan Kettering Cancer Center
NCT03587844
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
City of Hope Medical Center
NCT04930653
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Stanford University
NCT04256018
Extracorporeal Photopheresis in Sezary Syndrome
Oleg E. Akilov, MD, PhD
NCT05157581
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
NCT03602157
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
City of Hope Medical Center
NCT03011814
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
Washington University School of Medicine
NCT05944562
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
Memorial Sloan Kettering Cancer Center
NCT04960618
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
Eisai
NCT00050999
Effect of Denileukin Diftitox on Immune System in CTCL Patients
University of Pittsburgh
NCT00254332
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Ohio State University Comprehensive Cancer Center
NCT04312841
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
National Heart, Lung, and Blood Institute (NHLBI)
NCT00047060
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Sezary Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Sezary Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Sezary Syndrome page
14 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Sezary Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Sezary Syndrome trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sezary Syndrome condition card totals 14 registered trials; most-linked intervention ONTAK; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.